Announced
Completed
Financials
Tags
pharmaceutical
Netherlands
Acquisition
Cross Border
Minority
Private
Completed
Single Bidder
Pharmaceuticals
Private Equity
Friendly
Synopsis
Ampersand Capital Partners, a middle-market private equity firm, completed the investment in Julius Clinical Research, an academic research organization. Financial terms were not disclosed. "Julius Clinical Research is extremely pleased to have secured the support of Ampersand to help expand our expertise and geographic reach as a global research and scientific partner to pharmaceutical and biotechnology companies. We’ve been on a growth journey at Julius Clinical, driven by a combination of world-class scientific expertise and clinical study execution skills,” Martijn Wallert, Julius Clinical CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.